HBV-specific T-cell Immunity in Individuals With HIV/HBV Co-infection
NCT ID: NCT00476723
Last Updated: 2010-06-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
36 participants
OBSERVATIONAL
2005-04-30
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Towards a Functional Cure for HBV - The COMMIT Cohort Study
NCT03645044
Modified Dose and Schedule of Recombinant Hepatitis B Vaccination in HIV-infected Adult Subjects
NCT01289106
HIV-HBV Co-Infection and Liver Disease
NCT00637429
Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses
NCT06338826
A Surveillance Program for the Detection of Hepatitis B Virus (HBV) Resistance to Tenofovir in HIV-HBV co-Infected Patients
NCT00660361
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study population: Patients with HIV/HBV co-infection who are naive to HIV/HBV therapy, have detectable HBV viremia and are willing to start antiretroviral therapy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
HIV/Hepatitis coinfected patients who use at least one hepatitis activity drug or medications
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* hepatitis-B co-infected
* HBV/HIV therapy naive
* \>18 years of age
Exclusion Criteria
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kirby Institute
OTHER_GOV
Ministry of Health, Thailand
OTHER_GOV
The HIV Netherlands Australia Thailand Research Collaboration
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
HIV-NAT
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kiat Ruxrungtham, MD, MSc
Role: PRINCIPAL_INVESTIGATOR
HIV-NAT, The Thai Red Cross AIDS Research Centre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
HIV-NAT
Bangkok, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HIV-NAT 032
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.